Aegis is Awarded US Patent for Formulation and Non-invasive Delivery of Peptide Drugs
August 15, 2018 06:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded US Patent No. 10,046,025, providing non-invasive delivery of cyclic peptide drugs....
Aegis Expands its International and US Intravail® Patent Portfolio on Multiple Fronts
August 02, 2018 06:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded European Patent No. EP2381773(B1) and Canadian Patent No. 2,748,268, providing fast...
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
February 22, 2018 08:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple...
Aegis Announces Breakthrough in Non-Invasive, Rapid Onset, Acute Pain Control
October 10, 2017 08:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Aegis Therapeutics has developed a metered nasal spray formulation of hydromorphone having rapid onset of drug action (approximately 1 min. with a Tmax...
Aegis Therapeutics Announces Use of Intravail® in a Positive Phase 2 Study of DFN-02 for Acute Migraine
June 28, 2017 13:31 ET | Aegis Therapeutics LLC
SAN DIEGO, June 28, 2017 (GLOBE NEWSWIRE) -- Aegis Therapeutics announces positive Phase 2 results of DFN-02 using Intravail® technology. Dr. Reddy's Laboratories in collaboration with Promius...
Aegis Awarded 10th Patent for Fast Acting Migraine Nasal Spray Treatment
June 22, 2017 14:46 ET | Aegis Therapeutics LLC
SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded Korean Patent No. 1719008, providing fast acting formulations for triptans, a class of...
Aegis Awarded Patent for Non-invasive Nasal Anti-Seizure Drug Formulations
May 10, 2017 08:30 ET | Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - May 10, 2017) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,642,913, the fourth patent providing non-invasive metered nasal spray...
Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation
September 22, 2016 08:00 ET | Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - September 22, 2016) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,446,134 providing non-invasive metered nasal spray delivery of...
Aegis Awarded 9th Patent for Fast Acting Migraine Nasal Spray Treatment
August 30, 2016 08:00 ET | Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - August 30, 2016) - Aegis Therapeutics LLC announced today that it has been awarded Hong Kong Patent No. HK1164059 providing fast acting formulations for triptans, a...
Aegis Awarded 8th Patent for Fast Acting Migraine Nasal Spray Treatment
March 17, 2016 15:02 ET | Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - March 17, 2016) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,283,280, its eighth patent, third in the US, providing fast...